Sustainable vaccine development: a vaccine manufacturer's perspective
نویسندگان
چکیده
منابع مشابه
Development of Vaccine Adjuvants: a Historical Perspective
Since the earliest attempts to raise signifi cant immune responses against nonliving agents, investigators have tried to identify useful additives that can be combined with antigens to enhance immune responses. Such immuneenhancing additives are known as adjuvants. Virtually all adjuvant systems developed to date have focused on one of two mechanisms: specifi c immune activation or the delivery...
متن کاملDevelopment of male contraceptive vaccine--a perspective.
This paper reviews the recent advances that have occurred in the area of development of a male contraceptive vaccine. The vaccine candidates considered for review are hormone/hormone receptor-based proteins including luteinizing hormone-releasing hormone (LHRH)/LH, follicle stimulating hormone (FSH), as well as LH and FSH receptor proteins. The review also highlights the advances in our basic u...
متن کاملMalaria vaccine: a current perspective.
The observation that inactivated Plasmodium sporozoites could protect against malaria is about a hundred years old. However, systematic demonstration of protection using irradiated sporozoites occurred in the nineteen-sixties, providing the impetus for the development of a malaria vaccine. In 1983, the circumsporozoite protein (CSP), a major sporozoite surface antigen, became the first Plasmodi...
متن کاملPerspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
OBJECTIVE The goal was to understand vaccine manufacturers' perspectives on vaccine financing as a barrier to immunization. METHODS Individual telephone interviews with representatives of the 6 manufacturers that produce routinely recommended vaccines for children and adolescents in the United States were conducted in November and December 2006. RESULTS Although manufacturers acknowledged t...
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Immunology
سال: 2018
ISSN: 0952-7915
DOI: 10.1016/j.coi.2018.04.019